- Home
- LPAA vs STRO Comparison
LPAA vs STRO Comparison
Compare LPAA & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPAA
- STRO
- Stock Information
- Founded
- LPAA 2024
- STRO 2003
- Country
- LPAA United States
- STRO United States
- Employees
- LPAA N/A
- STRO N/A
- Industry
- LPAA
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPAA
- STRO Health Care
- Exchange
- LPAA Nasdaq
- STRO Nasdaq
- Market Cap
- LPAA 299.9M
- STRO 77.7M
- IPO Year
- LPAA 2024
- STRO 2018
- Fundamental
- Price
- LPAA $10.41
- STRO $0.75
- Analyst Decision
- LPAA
- STRO Hold
- Analyst Count
- LPAA 0
- STRO 7
- Target Price
- LPAA N/A
- STRO $3.97
- AVG Volume (30 Days)
- LPAA 65.1K
- STRO 1.2M
- Earning Date
- LPAA 01-01-0001
- STRO 08-12-2025
- Dividend Yield
- LPAA N/A
- STRO N/A
- EPS Growth
- LPAA N/A
- STRO N/A
- EPS
- LPAA 0.36
- STRO N/A
- Revenue
- LPAA N/A
- STRO $66,434,000.00
- Revenue This Year
- LPAA N/A
- STRO N/A
- Revenue Next Year
- LPAA N/A
- STRO N/A
- P/E Ratio
- LPAA $29.05
- STRO N/A
- Revenue Growth
- LPAA N/A
- STRO N/A
- 52 Week Low
- LPAA $9.66
- STRO $0.52
- 52 Week High
- LPAA $10.70
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- LPAA N/A
- STRO 44.48
- Support Level
- LPAA N/A
- STRO $0.73
- Resistance Level
- LPAA N/A
- STRO $0.79
- Average True Range (ATR)
- LPAA 0.00
- STRO 0.06
- MACD
- LPAA 0.00
- STRO 0.00
- Stochastic Oscillator
- LPAA 0.00
- STRO 40.20
About LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.